Artelo Biosciences to Present at the 6th Cannabinoid-Derived Drug Development Summit on September 12th
SOLANA BEACH, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical…
Month: September 2023
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology…
Capricor Therapeutics Appoints Michael Kelliher to Board of Directors
SAN DIEGO, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology…
PharmAla Begins Trading on OTCQB
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or…
PharmAla Begins Trading on OTCQB
VANCOUVER, British Columbia, Sept. 06, 2023 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or…
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the…
Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th
HAMILTON, BERMUDA , Sept. 06, 2023 (GLOBE NEWSWIRE) — Altamira Therapeutics Ltd. (“Altamira” or the…
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of…
Palisade Bio Transforms GI-Focused Pipeline Through Exclusive Worldwide Licensing Agreement with Giiant Pharma, Inc. for Multiple Oral Drug Candidates Targeting Inflammatory Bowel Disease
– Lead program, GT-2108 for the treatment of moderate-to-severe ulcerative colitis advancing toward completion of…
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
IO Biotech Announces Participation in Upcoming Investor Conferences
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference
WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX)…
NurExone Announces Closing of Second Tranche of Private Placement, bringing total raise at this round to approximately CAD$1.5M
TORONTO and HAIFA, Israel, Sept. 06, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX)…
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) announced today…
Enzo Biochem Announces Departure of Hamid Erfanian and Appointment of Kara Cannon as Interim CEO
FARMINGDALE, NY, Sept. 06, 2023 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) announced today…
Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
– Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous…
Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases
– Kriya envisions treating people with NASH using a one-time intramuscular gene therapy enabling continuous…
Vericel to Present at the Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) — Vericel Corporation (NASDAQ:VCEL), a leader in advanced…